370 related articles for article (PubMed ID: 19333947)
1. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study.
Norby GE; Holme I; Fellström B; Jardine A; Cole E; Abedini S; Holdaas H;
Arthritis Rheum; 2009 Apr; 60(4):1060-4. PubMed ID: 19333947
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation.
Holdaas H; Fellström B; Jardine AG; Nyberg G; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Ambühl P; Logan JO; Staffler B; Gimpelewicz C;
Nephrol Dial Transplant; 2005 May; 20(5):974-80. PubMed ID: 15784644
[TBL] [Abstract][Full Text] [Related]
3. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials.
Holdaas H; Wanner C; Abletshauser C; Gimpelewicz C; Isaacsohn J
Int J Cardiol; 2007 Apr; 117(1):64-74. PubMed ID: 16889855
[TBL] [Abstract][Full Text] [Related]
4. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
5. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV).
Dunkelgrun M; Boersma E; Schouten O; Koopman-van Gemert AW; van Poorten F; Bax JJ; Thomson IR; Poldermans D;
Ann Surg; 2009 Jun; 249(6):921-6. PubMed ID: 19474688
[TBL] [Abstract][Full Text] [Related]
6. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy.
Arampatzis CA; Goedhart D; Serruys PW; Saia F; Lemos PA; de Feyter P;
Am Heart J; 2005 Feb; 149(2):329-35. PubMed ID: 15846273
[TBL] [Abstract][Full Text] [Related]
7. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.
Holdaas H; Fellström B; Jardine AG; Holme I; Nyberg G; Fauchald P; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Ambühl P; Olsson AG; Hartmann A; Solbu DO; Pedersen TR;
Lancet; 2003 Jun; 361(9374):2024-31. PubMed ID: 12814712
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study.
Jardine AG; Fellström B; Logan JO; Cole E; Nyberg G; Grönhagen-Riska C; Madsen S; Neumayer HH; Maes B; Ambühl P; Olsson AG; Pedersen T; Holdaas H
Am J Kidney Dis; 2005 Sep; 46(3):529-36. PubMed ID: 16129216
[TBL] [Abstract][Full Text] [Related]
9. No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study.
Fellström B; Abedini S; Holdaas H; Jardine AG; Staffler B; Gimpelewicz C;
Clin Transplant; 2006; 20(6):732-9. PubMed ID: 17100723
[TBL] [Abstract][Full Text] [Related]
10. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy).
Lemos PA; Serruys PW; de Feyter P; Mercado NF; Goedhart D; Saia F; Arampatzis CA; Soares PR; Ciccone M; Arquati M; Cortellaro M; Rutsch W; Legrand V
Am J Cardiol; 2005 Feb; 95(4):445-51. PubMed ID: 15695126
[TBL] [Abstract][Full Text] [Related]
11. Cerebrovascular events in renal transplant recipients.
Abedini S; Holme I; Fellström B; Jardine A; Cole E; Maes B; Holdaas H;
Transplantation; 2009 Jan; 87(1):112-7. PubMed ID: 19136900
[TBL] [Abstract][Full Text] [Related]
12. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
13. Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials.
Winkler K; Ablethauser CB; Gimpelewicz C; Bortolini M; Isaacsohn JL
Clin Ther; 2007 Sep; 29(9):1987-2000. PubMed ID: 18035198
[TBL] [Abstract][Full Text] [Related]
14. Renal transplant dysfunction--importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality.
Soveri I; Holdaas H; Jardine A; Gimpelewicz C; Staffler B; Fellström B
Nephrol Dial Transplant; 2006 Aug; 21(8):2282-9. PubMed ID: 16574686
[TBL] [Abstract][Full Text] [Related]
15. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial.
Fellström B; Holdaas H; Jardine AG; Holme I; Nyberg G; Fauchald P; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Ambühl P; Olsson AG; Hartmann A; Logan JO; Pedersen TR;
Kidney Int; 2004 Oct; 66(4):1549-55. PubMed ID: 15458450
[TBL] [Abstract][Full Text] [Related]
16. Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus.
Tisseverasinghe A; Lim S; Greenwood C; Urowitz M; Gladman D; Fortin PR
Arthritis Rheum; 2006 Jul; 54(7):2211-9. PubMed ID: 16802357
[TBL] [Abstract][Full Text] [Related]
17. Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease.
Lemos PA; de Feyter PJ; Serruys PW; Saia F; Arampatzis CA; Disco C; Mercado N; Mainar V; Morís C; van den Bos AA; Berghoefer G
Int J Cardiol; 2005 Feb; 98(3):479-86. PubMed ID: 15708183
[TBL] [Abstract][Full Text] [Related]
18. Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients.
Ambrosi P; Aillaud MF; Habib G; Kreitmann B; Métras D; Luccioni R; Bouvenot G; Juhan-Vague I
Thromb Haemost; 2000 Jan; 83(1):46-8. PubMed ID: 10669153
[TBL] [Abstract][Full Text] [Related]
19. Comparison of efficacy and safety assessment of fluvastatin in patients <65 years versus > or =65 years of age.
Bruckert E; Verpilleux MP; Dejager S; Isaacsohn J
Am J Cardiol; 2005 Oct; 96(8):1142-8. PubMed ID: 16214453
[TBL] [Abstract][Full Text] [Related]
20. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double-blind, placebo-controlled trial.
Serón D; Oppenheimer F; Pallardó LM; Lauzurica R; Errasti P; Gomez-Huertas E; Bosmans JL; Sanchez-Plumed J; Romero R; Marques M; Fulladosa X; Moreso F
Transplantation; 2008 Jul; 86(1):82-7. PubMed ID: 18622282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
